We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA officials briefed members of the Drug Safety Oversight Board (DSOB) about safety activities in the Office of Drug Safety and the role of drug safety in the Office of New Drugs during the DSOB’s second meeting last month.